Abstract: Objective To systematically review the efficacy and safety of Saxagliptin combined with Insulin aspart 30 in the treatment of elderly （≥60） with type Ⅱdiabetes. Methods The databases including PubMed, EMBASE, ClinicalTrials.gov, Cochrane library, CNKI, CBM, Wanfang and VIP Data were searched from the inception to October 2018. The quality of included randomized controlled trials were assessed according to the Cochrane Handbook 5.1, And meta-analysis was performed by RevMan 5.3 software. Results Ten trials were included, involving 1 068 patients. Meta-analysis results showed, the total effective rate（RR=1.30,95%CI 1.18~1.43, P=0.000 01）was significantly improved in experimental group（Saxagliptin combined with Insulin Aspart 30） than those in control group（Insulin Aspart 30 only）. Compared with control group, experimental group could significantly reduce fasting blood glucose（MD=-1.64,95%CI -1.70~-1.57,P<0.000 01）、2-hour postprandial blood glucose（MD=-1.15,95%CI -1.22~-1.08,P<0.000 01）、body mass index（MD=-1.85,95%CI -2.62~-1.08,P<0.000 01）and the incidence of hypoglycemia（RR=0.21,95%CI 0.11~0.40,P<0.000 01）except for glycosylated hemoglobin A1（HbA1c）（MD=-0.37,95%CI -0.84~0.1,P=0.12）. Subgroup analysis showed that treatment lasted for 12 weeks, experimental group performed better in reducing HbA1c（MD=-1.16,95%CI -1.90~-0.43,P=0.002） than control group, by contrast, control group could significantly reduce HbA1c（MD=0.65,95%CI 0.57~0.72,P<0.000 01）with treatment lasted for 3 weeks. Conclusions Based on the current clinical evidence, Saxagliptin combined with Insulin Aspart 30 is an efficacious and safe choice for elderly type Ⅱ diabetic patient, but there is certain heterogeneity between the studies, therefore it is necessary for more high quality, large scale, multicenter, randomized controlled trial to be verified.